Sector consensus Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
NYSE
04:00:00 2026-09-25 pm EDT
|
5-day change | 1st Jan Change | ||
| 2.520 USD | +0.80% |
|
-12.50% | -8.36% |
| Sep. 20 | Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index | CI |
| Sep. 18 | William Blair Initiates Perspective Therapeutics With Outperform Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 12.29 | +387.53% | 14 | ||||||
| 688.17 | +20.9% | 23 | ||||||
| 277.94 | +2.8% | 18 | ||||||
| 253.92 | +23.88% | 22 | ||||||
| 432.8 | +19.94% | 28 | ||||||
| 267,786.94 | +50.95% | 22 | ||||||
| 581.83 | -5.99% | 12 | ||||||
| 72.24 | -6.61% | 14 | ||||||
| 272.16 | +38.36% | 20 | ||||||
| 68.56 | -19.36% | 18 | ||||||
| 298.79 | +2.03% | 14 | ||||||
| 185.25 | +7.5% | 16 | ||||||
| 3.908 | -28.61% | 7 | ||||||
| 70.73 | -2.59% | 11 | ||||||
| 50.57 | +16.26% | 11 | ||||||
| 138.64 | +23.84% | 22 | ||||||
| 46.27 | +4.72% | 15 | ||||||
| 174.69 | +23.14% | 13 | ||||||
| 135.01 | +64.84% | 7 | ||||||
| 638.68 | +127.47% | 19 | ||||||
| Average | 13,609.47 | +37.55% | 16 | ||||||
| Weighted average by Cap. | 21,547.22 | +17.60% | 19 |
- Stock Market
- Stocks
- CATX Stock
- Sector Perspective Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
